A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients

Inclusion Criteria: * Male or female 18 years or older * Patient diagnosed with Type 2 diabetes mellitus and chronic kidney disease * On a stable regimen of ACE inhibitors and/or ARB drugs for a minimum of 4 weeks * Not expected to start dialysis for one year * Patient has blood pressure less than or equal to 145/90 mm Hg * Patient has UACR greater than or equal to 200 mg/g if male and 300 mg/g if female but not more than 5000 mg/g * Patient has glycosylated hemoglobin A1c less than or equal to 10.5% Exclusion Criteria: * Patient has concurrent condition such as uncontrolled inflammatory disease, acute infection or other unstable illnesses * Patient has a history of allergy or sensitivity to pentoxifylline or methylxanthines * Patient has acute, active and/or unstable renal impairment or has been hospitalized for acute renal failure within the previous year * Patient has active malignancy or history of neoplastic disease * Patient has a QTc interval greater than 450 milliseconds * Patient has ALT or AST greater than 3 times the upper limit of normal or a potassium greater than or equal to 5.5mEq/L at screening * Patient is breast feeding or pregnant